Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Our Associate Company, Rhizen Pharmaceuticals SA ('Rhizen') has issued a Press Release announcing that it has received approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. Please find enclosed herewith Rhizen's press release. Alembic Pharmaceuticals Limited through its wholly owned subsidiary holds 50% ownership in Rhizen. We request you to kindly take the same on record.
02-12-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisements related to notice of loss of share certificate(s) published by the Company on behalf of the registered shareholder(s) or their legal heir(s) in English language newspaper - Business Standard on 1st December, 2020. We request you to kindly take the same on record.
01-12-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s) for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF). We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company.
26-11-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Tentative Approval for Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation). Please find enclosed herewith our press release. We request you to kindly take the same on record.
25-11-2020
Bigul

Why you should hold the stock of Alembic Pharma

 Reap the benefit of the company's planned expansions
22-11-2020
Bigul

Alembic Pharma gets tentative USFDA nod for breast cancer treatment drug

 Drug firm Alembic Pharmaceuticals said it has received tentative approval from the US health regulator for Palbociclib capsules, used to treat a certain type of breast cancer
09-11-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Palbociclib Capsules, 75 mg, 100 mg, and 125 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
09-11-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or legal heir(s) of the registered shareholders on 6th November, 2020 as per the attaced letter. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
06-11-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pranav Chirayu Amin
04-11-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CRA Family Trust & PACs
04-11-2020
Next Page
Close

Let's Open Free Demat Account